FOXO4-DRI 10mg Peptide

FOXO4-DRI is a designed peptide that interferes with a protein-protein interaction rather than binding a receptor or inhibiting an enzyme. Senescent cells resist apoptosis, and part of that resistance depends on the transcription factor FOXO4 binding p53 and holding it in the nucleus, where it cannot initiate the mitochondrial apoptotic programme. The peptide occupies that interaction site, releasing p53 to leave the nucleus and allowing the senescent cell to die.

The DRI in the name is the engineering. It stands for D-retro-inverso: the sequence is reversed and every residue is the D-enantiomer. That combination approximately preserves the arrangement of side chains in space, so the molecule still fits the interface it was designed against, while making it unrecognisable to proteases that evolved to cleave L-peptides. It is a general trick for turning a short interaction-blocking sequence into something with a usable half-life.

The selectivity argument is that healthy cells do not depend on the FOXO4 and p53 interaction for survival, so blocking it should kill senescent cells preferentially rather than being generally cytotoxic. Recent structural work has examined the target directly, reporting that the disordered p53 transactivation domain is what both FOXO4 and the peptide engage, which puts the mechanism on firmer footing than the original functional inference alone.

A short peptide that blocks a protein interaction is usually useless as a molecule because proteases destroy it within minutes. The D-retro-inverso approach addresses that without redesigning the binding surface.

Reversing the sequence and inverting the stereochemistry of every residue produces a molecule whose backbone runs the other way but whose side chains occupy approximately the same positions in space. The interface it was designed against still sees a compatible shape, while proteolytic enzymes, which are exquisitely selective for L-amino acid backbones, do not recognise it as a substrate.

The approximation is not perfect. Backbone hydrogen bonding differs between a peptide and its retro-inverso counterpart, so the strategy works well for interfaces dominated by side-chain contacts and poorly for those relying on backbone geometry. That it worked here says something about the FOXO4 and p53 interface as much as about the design.

The premise behind every senolytic is that senescent cells accumulate with age, secrete inflammatory mediators and drive dysfunction, so removing them should help. That premise is supported in several models and it is not universal.

Work in pulmonary hypertension reported that eliminating senescent cells promoted development and progression of the disease. Senescence is also a tumour-suppressive mechanism and a normal part of wound healing, so a cell that has stopped dividing is not automatically a cell that should be killed.

This is the most important thing to hold in view when reading about this compound, and it is usually absent from summaries. The question is not whether senolysis works but where clearing senescent cells helps and where it does harm, and that question is open.

There are no human trials of FOXO4-DRI. The evidence consists of mouse work, cell culture studies and structural characterisation of the target interaction. The founding study in aged and chemotoxicity-exposed mice remains the most cited result.

Peptide senolytics also face a delivery problem the literature does not fully solve. The target is an intracellular protein-protein interaction, so the molecule must cross the plasma membrane in sufficient quantity in the right cells, and cell-penetrating strategies are notoriously inefficient and hard to make selective.

The compound has no approval anywhere. Material supplied for research is for in-vitro laboratory use only, and nothing summarised here is guidance for use in humans or animals.

Because every residue is a D-enantiomer, standard enzymatic sequencing and digestion approaches will not work on this molecule. Proteases that would map an ordinary peptide do not cleave it, which is the point of the design but removes a common analytical tool.

Mass spectrometry does not distinguish enantiomers, so a mass consistent with the intended sequence is also consistent with the L-form or with a partially L-substituted synthesis. Confirming stereochemistry requires chiral analysis such as amino acid analysis after hydrolysis with chiral separation, which is a specific request worth making for a D-peptide rather than assuming.